PURPOSE: To synthesize and evaluate the antitumor efficacy of double-targeted docetaxel (DTX)-carboxymethyl chitosan (CMCS)-PEG-NGR (DTX-CPN) conjugates that could target to CD13 over-expressed tumor neovascular endothelium cells and tumor cells. METHODS: DTX was conjugated to CMCS via biodegradable linker and cNGR was applied to endow the conjugates with double targeting ability. The physiochemical properties and stability of this DTX-CPN conjugates were characterized. Cellular uptake study was carried out to evaluate the targeting ability of DTX-CPN conjugates. Cytotoxicity and apoptosis analysis were conducted to evaluate in vitro antitumor effects. In vivo antitumor efficacy was investigated in B16 murine melanoma model. RESULTS: DTX-CPN conjugates could self-assemble into nanoparticles in water and were stable in plasma. cNGR modification could promote the cellular uptake of DTX-CPN conjugates in CD13 positive HUVEC and B16 cells, leading to more significant cytotoxicity and apoptosis effect than non-targeted conjugates. DTX-CPN conjugates also exhibited better antitumor effect than non-targeted conjugates and Duopafei® in a B16 murine melanoma model. CONCLUSIONS: Double-targeted DTX-CPN conjugates could efficiently target to tumor neovascular cells and tumor cells, and achieve good antitumor effects. DTX-CPN conjugates may be promising candidate for one-double targeting cancer therapy.
PURPOSE: To synthesize and evaluate the antitumor efficacy of double-targeted docetaxel (DTX)-carboxymethyl chitosan (CMCS)-PEG-NGR (DTX-CPN) conjugates that could target to CD13 over-expressed tumor neovascular endothelium cells and tumor cells. METHODS:DTX was conjugated to CMCS via biodegradable linker and cNGR was applied to endow the conjugates with double targeting ability. The physiochemical properties and stability of this DTX-CPN conjugates were characterized. Cellular uptake study was carried out to evaluate the targeting ability of DTX-CPN conjugates. Cytotoxicity and apoptosis analysis were conducted to evaluate in vitro antitumor effects. In vivo antitumor efficacy was investigated in B16 murinemelanoma model. RESULTS:DTX-CPN conjugates could self-assemble into nanoparticles in water and were stable in plasma. cNGR modification could promote the cellular uptake of DTX-CPN conjugates in CD13 positive HUVEC and B16 cells, leading to more significant cytotoxicity and apoptosis effect than non-targeted conjugates. DTX-CPN conjugates also exhibited better antitumor effect than non-targeted conjugates and Duopafei® in a B16 murinemelanoma model. CONCLUSIONS: Double-targeted DTX-CPN conjugates could efficiently target to tumor neovascular cells and tumor cells, and achieve good antitumor effects. DTX-CPN conjugates may be promising candidate for one-double targeting cancer therapy.
Authors: Michael Dunne; Jinzi Zheng; Joshua Rosenblat; David A Jaffray; Christine Allen Journal: J Control Release Date: 2011-05-27 Impact factor: 9.776
Authors: Ahn Na Koo; Kyung Hyun Min; Hong Jae Lee; Sang-Uk Lee; Kwangmeyung Kim; Ick Chan Kwon; Sun Hang Cho; Seo Young Jeong; Sang Cheon Lee Journal: Biomaterials Date: 2011-11-29 Impact factor: 12.479
Authors: Corey J Langer; Kenneth J O'Byrne; Mark A Socinski; Sergei M Mikhailov; Krzysztof Leśniewski-Kmak; Martin Smakal; Tudor E Ciuleanu; Sergey V Orlov; Mircea Dediu; David Heigener; Amy J Eisenfeld; Larissa Sandalic; Fred B Oldham; Jack W Singer; Helen J Ross Journal: J Thorac Oncol Date: 2008-06 Impact factor: 15.609